newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • On July 1, 2026, Praxis Precision Medicines granted restricted stock unit awards covering 951 shares to five new non-executive employees.
  • The awards were issued under the 2024 Inducement Plan to serve as material inducements for new employment in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units will vest in four equal annual installments contingent upon continued employment with Praxis.
  • The 2024 Inducement Plan is exclusively designated for granting equity to individuals who were not previously employed by the company or returned after a bona fide period of non-employment.
  • Praxis is a CNS precision neuroscience biopharmaceutical company focused on developing therapies for neuronal excitation-inhibition imbalance using its Cerebrum™ small molecule platform & Solidus™ antisense oligonucleotide platform.
  • The company maintains a diversified CNS portfolio with four late-stage product candidates targeting movement disorders & epilepsy.